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Abstract
Hepatitis C virus (HCV) naturally infects only humans and chimpanzees. The determinants responsible for this narrow
species tropism are not well defined. Virus cell entry involves human scavenger receptor class B type I (SR-BI), CD81, claudin-
1 and occludin. Among these, at least CD81 and occludin are utilized in a highly species-specific fashion, thus contributing
to the narrow host range of HCV. We adapted HCV to mouse CD81 and identified three envelope glycoprotein mutations
which together enhance infection of cells with mouse or other rodent receptors approximately 100-fold. These mutations
enhanced interaction with human CD81 and increased exposure of the binding site for CD81 on the surface of virus
particles. These changes were accompanied by augmented susceptibility of adapted HCV to neutralization by E2-specific
antibodies indicative of major conformational changes of virus-resident E1/E2-complexes. Neutralization with CD81, SR-BI-
and claudin-1-specific antibodies and knock down of occludin expression by siRNAs indicate that the adapted virus remains
dependent on these host factors but apparently utilizes CD81, SR-BI and occludin with increased efficiency. Importantly,
adapted E1/E2 complexes mediate HCV cell entry into mouse cells in the absence of human entry factors. These results
further our knowledge of HCV receptor interactions and indicate that three glycoprotein mutations are sufficient to
overcome the species-specific restriction of HCV cell entry into mouse cells. Moreover, these findings should contribute to
the development of an immunocompetent small animal model fully permissive to HCV.
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Introduction
HCV is an enveloped virus with a positive sense single stranded
RNA genome, belonging to the family of Flaviviridae [1]. Based on
sequence comparison patient isolates are classified into seven
genotypes which differ from each other by ca. 31–33% at the
nucleotide level [2,3]. Chronic hepatitis C is associated with severe
liver disease including hepatitis, liver cirrhosis and hepatocellular
carcinoma and it is the most frequent indication for liver
transplantation [4]. Presently, neither therapeutic nor preventive
vaccines are available and the only current therapy, a combination
of pegylated interferon-a and ribavirin, is limited by resistance,
toxicity and high costs [5].
Development of HCV-specific antivirals and vaccines has been
impeded by lack of convenient animal models. Besides humans the
only host for HCV is the chimpanzee and an immunocompetent
small animal model is still lacking. The restricted tropism of HCV
likely reflects specific host factor requirements for entry, RNA-
replication, assembly and release of virions. Although mouse cells
have been shown to sustain HCV RNA replication [6], the
efficiency is low and release of progeny virus particles was not
observed [7]. Moreover, cell entry of HCV into rodent cells is
possible, but requires overexpression of essential human entry
factors [8]. Therefore, propagation of HCV in mouse cells is likely
restricted at multiple steps of the viral replication cycle.
HCV cell entry is a complex process involving a number of host
factors. Initial adsorption of viral particles consisting of core
protein, envelope proteins 1 and 2 (E1, E2) and associated with
lipoproteins [9–11], may be facilitated by attachment factors like
glycosaminoglycans [12], the LDL receptor [13,14] and lectins
[15–17]. Beyond these, four essential HCV entry factors have
been identified: the scavenger receptor class B type 1 (SR-BI) the
tetraspanin CD81 and the tight junction proteins claudin-1
(CLDN1) and occludin (OCLN) [8,18–22]. Usage of these four
factors mediates clathrin-dependent endocytosis [23] of virus
particles and ultimately permits viral membrane fusion in a low
pH-triggered fashion [24]. Notably, ectopic expression of human
SR-BI, CD81, CLDN1 and OCLN rendered all cell lines tested
permissive for HCV suggesting that additional host factors
necessary for host cell entry are broadly expressed and conserved
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ing evidence indicates that a species-specific interplay of HCV
with these four entry factors restricts HCV entry into non-human
cells and thus contributes to HCV’s narrow species tropism
[25–27]. Particularly, inefficient usage of non-human CD81 and
OCLN by HCV seems to limit viral entry into non-human cells
[8]. However, more recently evidence was provided that mouse
SR-BI and at least for genotype 2a also mouse CLDN1 supported
HCV infection with slightly lower efficiency compared to their
human homologs [26,27], implying that incompatibility of these
factors may also limit HCV entry into mouse cells.
The interaction between the viral glycoprotein E2 and CD81
has been analyzed using truncated, soluble E2 and retroviral
pseudoparticles bearing the HCV glycoproteins E1 and E2
(HCVpp). These studies highlight that defined residues within
the large extracellular loop (LEL) of CD81, a protein domain that
is highly variable between CD81 isoforms from different species,
are crucial for interaction with HCV E2 [28,29]. On the other
hand, the viral binding site for CD81 seems to be a conformational
epitope within E2: Based on reverse genetics and antibody
competition experiments with E2-specific antibodies, multiple
discontinuous epitopes have been implicated in CD81 binding
[30–34].
To characterize viral determinants for CD81 usage and to assess
if improved utilization of mouse CD81 is sufficient to permit entry
of HCV into mouse cells, we adapted HCV to mouse CD81, and
analyzed the consequences for virus receptor interaction and
tropism.
Results
Adaptation of HCV to mouse CD81
For adaptation of HCV to mouse CD81, we first created Huh7-
Lunet cells [35] that are highly permissive for HCV RNA
replication and virus production but that are essentially not
infectable due to limiting expression of endogenous human
CD81. This cell clone designated Lunet N [36] was created by
fluorescence activated cell sorting for cells expressing very little
CD81. The resulting cell population was subcloned and individual
clones were analyzed for CD81 expression and permissiveness for
HCV RNA replication. Ultimately, a subclone with minimal
residual CD81 expression supporting high level HCV RNA
replication was selected. In the absence of ectopically expressed
CD81, these cells designated Lunet N cells are essentially refractory
to HCV infection (Figure S1). Susceptibility of these cells to HCV
infection was restored by ectopic expression of human or mouse
CD81. However, in agreement with the results of Flint et al. [25],
mouse CD81 supported infection approximately 100-fold less
efficiently than human CD81 (Figure S1). Next, we transfected
Lunet cells expressing mouse CD81 (Lunet N mCD81) with the
HCV genotype 2a chimeric virus Jc1 that grows to high virus titers
[37]. After five cell passages, naive Lunet N mCD81 cells were
added to the culture and nine additional cell passages later, virus
had spread to nearly all cells of the co-culture (data not shown). At
this time point, four consecutive passages of cell-free culture fluid to
naı ¨ve Lunet N mCD81 cells were conducted to select for virus
variants that efficiently use mouse CD81 (Figure 1A). At individual
passage steps of the procedure, we sampled the infectivity of the
virus population present on cells expressing either human, mouse or
no CD81 to monitor the progress of adaptation.
In the course of this experiment, viruses were selected that
remained dependent on CD81 but which were able to use mouse
and human CD81 with comparable efficiency (Figure S2). HCV
RNA derived from the final supernatant passage was isolated and
sequenced. In the region of the genome encoding the viral
structural proteins Core, E1, E2 as well as p7, NS2 and NS3, we
identified four mutations that were conserved at least among 4 out
of the 6 sequenced clones (Figure 1B). Three of these mutations
were located in the viral glycoproteins; one in E1 (L216F) and two
in E2 (V388G and M405T). Both mutations located in E2 reside
within the hypervariable region 1 (HVR1), a stretch of 27 amino
acids at the N-terminus of E2 which has been implicated to
interact with SR-BI [38]. The fourth mutation was detected in the
first transmembrane domain of the p7 protein (N767D). To
analyze the influence of these amino acid changes on RNA-
replication, virus production and infection of cells expressing
human or mouse CD81, we transferred them individually or in
combinations into the backbone of Jc1. These constructs were
then transfected into naı ¨ve Huh-7.5 cells, and intracellular as well
as extracellular core protein levels were determined to assess
replication and virus release (Figure 1C–1D). Finally, cell-free
culture fluids were harvested, normalized for equal quantity of
core and then used to infect Lunet N cells expressing either human
or mouse CD81 (Figure 1E). None of the mutations individually or
in combination markedly affected RNA-replication and virus
release, as is evident from comparable levels of intracellular core
48 h post transfection of these constructs and from a similar
efficiency of core protein release at this time point (Figure 1C–1D).
The mutation in p7 did not affect virus entry into cells with mouse
or human CD81 and thus CD81 usage. In contrast, all three
mutations in the glycoproteins moderately increased the efficiency
of the virus to infect cells carrying mouse CD81 compared to the
parental Jc1 chimera (Figure 1E) thus suggesting that these
changes enhance the ability of the virus to use mouse CD81.
Interestingly, L216F and V388G at the same time reduced
efficiency of infection via the human CD81 counterpart. In
contrast, the M405T mutation stimulated infection through mouse
CD81 without affecting entry via human CD81. Strikingly, the
combination of all three glycoprotein-resident mutations as well as
all four mutations together, increased infection mediated by mouse
CD81 to the levels sustained by human CD81 (Figure 1E).
Author Summary
The hepatitis C virus (HCV) infects only humans and
chimpanzees, which has hampered development of
suitable animal models. The inability of HCV to penetrate
non-human cells is primarily due to inefficient usage of
non-human CD81 and occludin. In this study we adapted
HCV to mouse CD81. Efficient utilization of mouse CD81 is
conferred by a combination of three mutations in the viral
glycoproteins. These changes also permit entry via rat or
hamster CD81, and lower viral dependence on additional
HCV entry factors. Strikingly, mouse CD81 adapted HCV
glycoproteins mediate entry into mouse cells in the
absence of human entry factors. The adaptive mutations
are not resident in viral domains implicated in direct CD81
binding. Nevertheless, they enhance binding to human
CD81, increase susceptibility to different neutralizing
antibodies and facilitate induction of viral cell fusion by
low pH. This suggests that structural changes accompa-
nied by exposure of the CD81 binding site and neutralizing
epitopes have ‘‘unlocked’’ the viral envelope protein
complex facilitating infection through non-human entry
factors. These results highlight mechanisms of HCV
receptor usage and tropism. They also demonstrate that
HCV can be adapted to using non-human host factors,
which may ultimately facilitate the development of small
animal models.
Adaptation of HCV to Mouse CD81
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V388G and M405T mutations (designated Jc1/mCD81) on Lunet
N mCD81 cells was efficiently neutralized by antibodies specific to
mouse CD81 but not by antibodies directed against human CD81,
thus indicating that the virus indeed uses the mouse entry factor
for infection (data not shown).
To address if these mutations specifically permit infection via
mouse CD81 or if they would also increase HCV infection
through CD81 from other rodent species, we cloned rat and
hamster CD81 and stably transduced Lunet N cells with these
orthologs. These cells were challenged with equal quantities of Jc1
and Jc1/mCD81 particles. Similar to the mouse ortholog,
Figure 1. Adaptation of Jc1 to mouse CD81. (A) Schematic overview of the process of adaptation. Lunet N mCD81 cells were transfected with
Jc1 RNA by electroporation (arrow), passaged 5 times and then mixed with untransfected Lunet N mCD81 cells (mix). The cells were continuously
passaged until the virus had spread to the whole cell population (mix P1–P9) followed by four consecutive supernatant passages (SP). RNA from the
fourth SP was extracted, cloned and sequenced. (B) Jc1 genome organization. The viral glycoproteins E1 and E2 and the p7 ion channel protein are
enlarged. The mutations identified by sequencing of the passaged virus population are indicated with stars. J6CF-derived proteins segments are
depicted by white boxes, JFH1-derived proteins are shaded in grey. Transmembrane domains (TMD) of E1 and E2 are depicted in black. HVR1,
hypervariable region 1. (C+D) Huh-7.5 cells were transfected with Jc1 and indicated Jc1-based mutant RNAs. The amount of intracellular core protein
in cell lysates (C) and the percent of total core protein production released into the extracellular space was determined 48 h post transfection by a
core-specific ELISA (D). Mean values of duplicate measurements and the standard deviation of the means are given. (E) Infectivity of Jc1 and indicated
Jc1 derivatives was determined on Lunet N cells expressing either human or mouse CD81 using the limiting dilution assay (TCID50). Prior to titration
virus preparations were normalized for equal quantity of core protein.
doi:10.1371/journal.ppat.1000978.g001
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fold more efficient with Jc1/mCD81 compared to parental Jc1
(Figure 2). Thus, these three mutations within HCV E1 and E2
enhance entry efficiency of HCV through mouse, rat and hamster
CD81 to a comparable degree suggesting that the adaptation was
not specific to mouse CD81 only. It is worth mentioning here that
both parental Jc1 and Jc1/mCD81 infected Lunet N cells, albeit
with very low efficiency (Figure 2). Since this low level infectivity
was susceptible to neutralization by CD81-specific antibodies it is
likely due to very low residual levels of human CD81 in these cells
rather than due to a CD81-independent route of virus entry (data
not shown).
Adaptation enhances HCV interaction with soluble
human CD81 and increases exposure of the viral CD81
binding site
It is conceivable that improved usage of mouse CD81 by HCV
may be linked with augmentation of the affinity between the
adapted viral glycoproteins and CD81. Therefore, we assessed
whether these mutations altered the interaction between the viral
E1/E2 glycoprotein complexes and CD81. To this end, we
utilized a recombinant fusion protein between GST and the
human CD81 large extracellular loop (LEL) which encompasses
the viral binding site and has previously been used to probe this
interaction [28,29]. To distinguish possible changes of virus
receptor usage of mouse CD81 adapted glycoproteins from altered
receptor usage caused by cell culture adaptation of HCV after long
term passage, we created an additional virus mutant in the context
of the Jc1 chimera which harbours a single G451R mutation
within the E2 protein. This mutation was originally identified in
the JFH1 isolate upon long term passage [39] and the G451
position is conserved between the JFH1 isolate and the J6CF strain
of HCV as present in the Jc1 chimera. More recently, the G451R
mutation was shown to increase the interaction of JFH1 E2 with
CD81 and to reduce virus dependence on SR-BI [40]. Unlike Jc1/
mCD81, Jc1/G451R still displays a strong preference for infection
via human rather than mouse CD81 (Figure S3). Interestingly,
when we performed infections in the presence of increasing doses
of the GST hCD81 LEL, the fusion protein only poorly
neutralized infection by parental Jc1 (Figure 3A). These data
indicate that soluble human CD81 does not efficiently compete
with cell surface resident CD81 during infection of parental Jc1. In
contrast preincubation of Jc1 variants with 10 mg/ml hCD81 LEL
reduced infection by these viruses more than 10-fold, suggesting
Figure 2. Adaptive mutations increase HCV cell entry via
different rodent CD81 molecules. Jc1 and Jc1/mCD81 stocks were
generated by transfection of Huh-7.5 cells. Cell supernatants were
collected 48 h after tansfection and titrated on the indicated cell lines
using the limiting dilution assay. The dashed line indicates the
detection limit of the limiting dilution assay.
doi:10.1371/journal.ppat.1000978.g002
Figure 3. Interaction of HCV wildtype and mutant glycopro-
teins with recombinant CD81. (A) Neutralization with GST or GST-
hCD81 LEL fusion proteins: Cell culture supernatant harvested from
Huh-7.5 cells transfected with indicated luciferase reporter virus
constructs were preincubated with varying amounts of the indicated
recombinant proteins for 30 minutes at room temperature. Subse-
quently, mixtures were used to inoculate Lunet N hCD81 cells. Cells
were lysed 72 h post infection; the firefly luciferase activity was
measured and is given in percent relative to control infection in the
absence of GST proteins. Mean values of triplicate measurements
including the standard deviation are given. (B) Viruses from cell culture
supernatant of Huh-7.5 cells transfected with the indicated RNA
genomes and normalized for equal amount of core protein were
precipitated by GST or human CD81-LEL GST fusion proteins coupled to
glutathione agarose beads. The amount of precipitated virus was
determined by quantitative RT-PCR.
doi:10.1371/journal.ppat.1000978.g003
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soluble human CD81 protein (Figure 3A). Similarly, both viruses
with adapted glycoproteins were also precipitated more efficiently
by hCD81LEL as is evident from 2-3-fold higher amounts of HCV
RNA associated with hCD81LEL coated beads incubated with
Jc1/mCD81 or Jc1/G451R compared to beads incubated with an
equal amount of wildtype Jc1 particles (Figure 3B). Thus, both the
cell culture adaptive mutation G451R and the triple mutation
identified by us increased interaction with soluble human CD81
possibly by enhancing the exposure of the viral CD81 binding site.
Mouse CD81 adapted HCV uses human CD81 with
increased efficiency
To assess if increased binding of Jc1/mCD81 to human CD81
correlates with altered receptor usage during virus entry, we used
two complementary approaches: First, we analyzed susceptibility
of Jc1/mCD81 infection to neutralization with anti-human CD81
antibodies (Figure 4A). Second, we quantified the threshold level
of human CD81 needed for productive infection of Huh7-Lunet
cells (Figure 4B and S4). Interestingly, selectively Jc1/mCD81 was
more resistant to neutralization by anti-human CD81 antibodies
compared to the parental Jc1 virus and compared to Jc1/G451R
(Figure 4A). These results imply that Jc1/mCD81 competes more
efficiently with CD81-antibodies for available CD81 binding sites
on the cell surface. To determine the minimal CD81 threshold
surface expression needed for infection by these viruses, parental
Huh7-Lunet cells displaying low to moderate CD81 surface
expression were mixed with Lunet N hCD81 cells expressing high
levels of CD81 to create a mixed cell population containing cells
with highly divergent CD81 abundance at the cell surface.
Subsequently these cells were challenged with Venus-GFP-
expressing HCV reporter viruses normalized for equal quantity
of core protein [41]. Using this approach the relation between
CD81 cell surface level and infection efficiency can be quantified
using a dual colour FACS analysis [41]. Jc1/mCD81 infected up
to 71% of cells with high CD81 expression (ca. 1,000 MFI)
compared to Jc1 and Jc1/G451R infecting only 38.9% and 34%
of cells with this CD81 abundance (Figure 4B and S4). However,
this increased efficiency of Jc1/mCD81 was not accompanied by a
reduction of the minimal threshold density of CD81 required for
entry since the turning point of the curves which describe the
relation between CD81 receptor density and % infected cells was
not significantly different between the three viruses compared (Jc1
MFI 55.70; Jc1/mCD81 MFI 57.74; Jc1/G451R MFI 54.90; p-
value .0.5). Therefore, we conclude that all three viruses share a
similar minimal human CD81 receptor density to permit infection.
However, selectively Jc1/mCD81 has attained a higher efficiency
of infection in cells displaying CD81 levels in excess of the minimal
CD81 level. Together these results argue that Jc1/mCD81 uses
human CD81 with elevated efficiency, suggesting either that the
avidity (the combined strength of multiple interactions) of the virus
for human CD81 has increased and/or that the threshold avidity
needed for proper CD81 usage was lowered.
Figure 4. Efficiency of human CD81 usage by Jc1 and Jc1
variants. (A) Neutralization with antibodies specific for human CD81:
Indicated viruses (luciferase reporter viruses) were mixed with different
concentrations of the human CD81-specific monoclonal antibodies 5A6
or 1.3.3.22. Alternatively, viruses were mixed with CD13-specific control
antibodies. Subsequently, mixtures were used to inoculate Lunet N
hCD81 cells. Infectivity was determined and expressed as described in
the legend of figure 3. (B) Determination of the threshold level of CD81
needed for infection: Naı ¨ve Huh7-Lunet cells were mixed with Lunet N
hCD81 cells in a ratio of 1:1 and were infected with indicated Venus Jc1
reporter viruses normalized for equal amounts of core protein. 72 h
after infection the cells were harvested, fixed and stained for CD81 with
the CD81 specific antibody 5A6 and a secondary antibody coupled to
APC. The Venus GFP signal was plotted against the CD81 expression
and the percentage of HCV infected cells at a given CD81 cell surface
expression was calculated. The graph displays the percentage of HCV
infected cells as a function of CD81 expression level plotted as mean
fluorescence intensity (MFI). A representative experiment carried out in
duplicates is given. Dashed lines indicate the turning points of the
individual curves. FACS dot plots of the experiment are shown as
supplementary figureS4.
doi:10.1371/journal.ppat.1000978.g004
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SR-BI and OCLN
Next, we analyzed if the adaptation of HCV to mouse CD81
has influenced the utilization of human SR-BI, CLDN1 or OCLN.
To this end we employed SR-BI- and CLDN1-specific and control
antibodies for receptor competition assays comparing parental Jc1
with Jc1/mCD81 and Jc1/G451R (Figure 5A–5C). Since OCLN-
specific neutralizing antibodies are not available, we assessed the
dependence of these viruses on OCLN surface expression using
RNA interference (Figure 5D). Our data indicate that all viruses
compared by us need CLDN1 for cell entry, since receptor-specific
antibodies inhibited infection by each virus in a dose-dependent
fashion (Figure 5A). Dependence of all three viruses on CLDN1
was also confirmed by inoculation of HuH6 cells which express
only minimal amounts of CLDN1, rendering them refractory to
Jc1 infection [26] and also to both adapted viruses (data not
shown). Notably, virus neutralization through SR-BI-specific
antibodies was clearly less efficient for Jc1/G451R and Jc1/
mCD81 compared to parental Jc1 particles reducing infectivity to
approximately 80% only compared to 5%, respectively (Figure 5B).
These data confirm the findings of Grove et al., who observed a
similar phenotype for JFH1/G451R [40] and indicate that both
virus mutants are less dependent on SR-BI for cell entry. Finally,
knock down of OCLN reduced efficiency of cell entry for all three
viruses, although the reduction was less pronounced for Jc1/
mCD81 (p,0.001) (Figure 5D). In conclusion these results suggest
that adaptation to mouse CD81 has not only lowered dependence
on human CD81 but also on SR-BI and OCLN expression.
HCV usage of mouse CD81 is accompanied by exposure
of neutralizing epitopes and altered requirements for low
pH-induced cell entry
Since structural information of the HCV E1/E2 complex is not
available, we performed a series of virus neutralization experi-
ments using well defined E2-specific monoclonal antibodies with a
conserved linear epitope or conformational binding sites in order
to document structural changes of the E1/E2 complex that may be
responsible for the phenotypic changes of adapted HCV. More
specifically, we used AP33 a mouse monoclonal antibody
recognizing a linear epitope within E2 [42], and three human
monoclonal antibodies interacting with three distinct conforma-
tional domains on the E1/E2 complex designated A, B and C
[43,44]. Antibodies interacting with domain A like CBH4D are
non-neutralizing, whereas antibodies to domains B or C (e.g.
CBH5 or CBH23, respectively) inhibit E2 binding to CD81 and
neutralize infection of HCVpp and HCVcc from genotypes 1 and
2 [45,46].
As expected, even high doses of the non-neutralizing antibody
CBH4D and the R04 antibody which recognizes a protein of the
cytomegalovirus, did not interfere with infection of all three viruses
tested (Figure 6). AP33, CBH5 and CBH23 did not markedly
neutralize Jc1. In contrast, these antibodies neutralized Jc1/
Figure 5. Dependence of wildtype and mutant HCV on SR-BI, CLDN1 and OCLN. (A–C) Neutralisation of indicated viruses with purified
immunoglobulins from rats immunized with CLDN1 (A) or SR-BI (B) cDNAs. Immunoglobulins purified from naı ¨ve rats served as control (C). Infectivity
was determined as described in Figure 3 and is expressed relative to infections conducted in the absence of antibodies. Mean values of triplicate
measurements including the standard deviation are given. (D) OCLN expression in Lunet N hCD81 cells was downregulated by transfection with
siRNAs specific to OCLN mRNA. A scrambled siRNA was transfected in parallel and served as control. Knock down efficiency was monitored by lysing a
fraction of the cells at the time point of inoculation with indicated luciferase reporter viruses. Infectivity was determined 48 h later and is expressed
relative to the one measured in cells transfected with the control siRNA. Mean values of triplicates including the standard deviation are shown.
doi:10.1371/journal.ppat.1000978.g005
Adaptation of HCV to Mouse CD81
PLoS Pathogens | www.plospathogens.org 6 July 2010 | Volume 6 | Issue 7 | e1000978mCD81 and Jc1/G451R infection in a dose-dependent fashion,
indicating that both adapted viruses are much more prone to
neutralization by E2-specific antibodies (Figure 6). Notably,
domain C antibody (CBH23) neutralized Jc1/mCD81 and Jc1/
G451R to a different degree with Jc1/mCD81 being more
susceptible to the antibody (IC90 of Jc1/mCD81 and Jc1/G451R:
12.9 mg/ml and 157.3 mg/ml, respectively, p,0.001). In contrast,
both viruses were similarly neutralized with the AP33 antibody
(IC90 of Jc1/mCD81 and Jc1/G451R: 0.27 and 0.07 mg/ml,
respectively, p=0.28) and with the domain B antibody (CBH5;
IC90 of Jc1/mCD81 and Jc1/G451R: 0.18 and 0.07 mg/ml,
respectively, p=0.18). The differential susceptibility to neutraliz-
ing antibodies was not due to overtly different buoyant density of
these viruses (Figure S5) and is indicative of distinct structures of
the respective viral glycoprotein complexes. These in turn are
likely responsible for the different phenotypes regarding host entry
factor usage and tropism.
After cell surface binding and virus internalization into clathrin-
coated pits, HCV infection is mediated by conformational changes
of the viral glycoprotein complex E1/E2 which are triggered by
low pH [24]. Notably, the responsiveness of HCV to low pH-
triggered fusion seems to change over time: First, unlike for
Figure 6. Neutralization of wildtype and mutant HCV with E2-specific antibodies. Given viruses were precincubated for 30 minutes at
room temperature with indicated doses of human monoclonal antibodies or the mouse monoclonal antibody AP33. Subsequently, mixtures were
used to inoculate Lunet N hCD81 cells. Infectivity was determined as described in figure 3 and is expressed relative to infections conducted in the
absence of antibodies. Mean values of triplicates including the standard deviations are given. The RO4 human monoclonal antibody recognizes a
cytomegalovirus protein and was used as control.
doi:10.1371/journal.ppat.1000978.g006
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fashion and which are inactivated by low pH-treatment in
solution, HCV resists such treatment and retains infectivity [24].
Second, exposing HCV particles directly after binding to
permissive cells at 4uC, a temperature which allows binding of
the viral particles, but no further steps of the entry process, to a
low pH wash does not efficiently initiate infection. In contrast,
chasing these particles for 1 h at 37uC increases their sensitivity to
low pH which may indicate that HCV requires certain additional
stimuli like for instance receptor interactions to prepare the virus
for low pH-triggered fusion and infection [24]. Given these
findings, we hypothesized that adaptation to mouse CD81 may
have selected for altered E1/E2 complexes that are more
responsive to conformational changes triggered by receptor
interactions and/or low pH, thus permitting entry through use
of an entry factor of non-human origin with poor binding affinity
for HCV. To test this hypothesis we compared the responsiveness
of Jc1, Jc1/mCD81 and Jc1/G451R to low pH-treatment directly
after cell surface binding and 1 h later following the protocol
described by Tscherne et al. [24]. Importantly, infection via
acidified endosomes is blocked throughout these experiments by
treatment of target cells with concanamycin A (ConA). Since this
drug inhibits endosomal V-ATPases, acidification of endosomes is
inhibited thus ablating infection through the natural endosomal
route [24]. In agreement with the observation by Tscherne et al.,
treatment with pH 5 directly after virus binding at 4uC stimulated
Jc1 infection with very low efficiency, reaching only ca. 4% of the
infection attained when acidification of endosomes was not
blocked by addition of ConA and viruses were treated with
pH 7 only (Figure 7A). Infectivity of both Jc1/mCD81 and Jc1/
G451R was comparable to Jc1 when washed with pH 7 ranging
between 1 and 3% of control infections in the absence of ConA.
However, both viruses strongly responded to the pH 5 wash
already directly after virus binding reaching up to 30% and 20%
of the untreated control. After incubation of cell-bound HCV for
1 h at 37uC also Jc1 particles could be stimulated to infect ConA-
treated cells (Figure 7B). Therefore, unlike wildtype HCV both
adapted viruses can be triggered to infect ConA-treated cells
already directly after cell surface binding suggesting that the
requirements for induction of infection by low pH have been
modified.
Adaptive mutations within E1/E2 permit HCV infection of
mouse cells
Finally, we analyzed if the mutations selected by adaptation of
Jc1 to mouse CD81 permit HCV infection of mouse cells in the
absence of human factors. For these experiments we chose
NIH3T3 cells which become susceptible to HCVpp by ectopic
expression of human SR-BI, CD81, CLDN1 and OCLN [8].
While these cells express endogenous mouse CD81 and mouse
SR-BI, we were unable to detect mouse CLDN1 and OCLN
(Figure S6). Given these circumstances, we created NIH3T3-
derived cell lines which ectopically express all four human or
mouse HCV entry factors, designated NIH3T3-4xH or NIH3T3-
4xM. Since mouse cells support very low HCV RNA replication,
we used murine leukemia virus-based HCV pseudoparticles
(HCVpp) transducing a Venus-GFP reporter gene to quantify
HCV cell entry into these cells. As expected, HCVpp with
wildtype or mouse CD81 adapted glycoproteins were unable to
infect control NIH3T3 cells but efficiently entered Lunet N
hCD81 cells (Figures 8A and S7A). Ectopic expression of human
HCV entry factors in NIH3T3 cells rendered these cells permissive
to both wildtype HCV and mouse CD81 adapted HCVpp,
reaching infectivities as high as ca. 20% and 60% of the infectivity
in Lunet N hCD81 cells, respectively. In contrast, NIH3T3 cells
expressing mouse entry factors (NIH3T3 4xM) were only
efficiently infected with HCVpp carrying mouse CD81 adapted
glycoproteins. Importantly, HCVpp coated with mouse CD81
adapted glycoproteins infected NIH3T3 cells with human or
mouse entry factors with comparable efficiency and infectivity of
HCVpp was efficiently neutralized by anti-human or anti-mouse
CD81 antibodies in the respective cell lines (Figures 8B and S7B).
In agreement with our data described above, HCVpp coated with
wildtype J6 glycoproteins were more prone to neutralization by
anti-CD81 antibodies compared to J6/mCD81-coated HCVpp.
In conclusion these results indicate that three adaptive mutations
within HCV E1/E2 proteins are sufficient to permit efficient HCV
Figure 7. Induction of HCV cell entry by low pH treatment.
Lunet N hCD81 cells were pretreated with Concanamycin A (ConA) at a
concentration of 5 nM to prevent acidification of cellular endosomes
and thus the natural route of HCV cell entry. Pretreated cells were
inoculated with given F-Luc Jc1 variants in the presence of ConA at 4uC
for 2 h. Cells were washed twice with cold PBS either directly followed
by an incubation in citric acid buffer of pH 7 or pH 5 for 5 min at 37uC
(A). Alternatively, the cells were first shifted to a temperature of 37uC
and were incubated for 1 h in the continued presence of ConA before
they were incubated with citric acid buffer of pH 5 or pH 7 for 5
minutes (B). Thereafter, cells were cultured an additional 3 h in the
presence of 5 nM ConA before the medium was changed. Cells were
lysed after 48 h; the luciferase signal was measured and is expressed
relative to control infections conducted in the absence of ConA and
where the cells were incubated with citric buffer of pH 7. Mean values
of triplicate measurements including the standard deviation are given.
doi:10.1371/journal.ppat.1000978.g007
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unable to detect productive entry of HCVpp with wildtype or
mouse CD81-adapted glycoproteins into primary mouse hepato-
cytes. We cannot exclude that dominant restriction factors
expressed in these cells may limit cell entry even of mouse
adapted HCVpp. However, we observed very low expression of
mouse CLDN1 and undetectable quantities of mouse OCLN in
these cells (Fig. S8) which very likely precludes efficient HCV cell
entry.
Discussion
In this study we took advantage of a human liver cell line
expressing mouse in place of human CD81 to select for a
population of HCV that utilizes this entry factor with high
efficiency for infection of host cells. Employing reverse genetics we
showed that the ability to utilize mouse CD81 was conferred by a
combination of three mutations within the viral surface proteins
E1 and E2.
In principle, change of receptor usage mediated by these
mutations may reflect an adaptation of the viral CD81 binding
site to accommodate the mouse entry factor and to enhance binding
affinity. However, neither these residues nor the domains in which
they are located in have previously been implicated in the virus-
CD81 interaction. Two of the identified mutations (V388G and
M405T) are part of the so called hypervariable region 1 (HVR1).
This highly variable domain at the N-terminus of E2 has been
implicated in the interaction with SR-BI [47,48] and is dispensable
for binding of soluble E2 to CD81 [31]. In fact, deletion of HVR1
enhances binding of soluble E2 to soluble or cell surface-bound
CD81 [31]. In addition viruses lacking HVR1 are only moderately
impaired in entry and remain susceptible to neutralization by
CD81-specific antibodies [48], thus strongly suggesting that the
HVR1 is dispensable for the interaction with CD81. Consequently,
it is unlikely that the HVR1 is part of the viral CD81 binding site
and that the adaptive mutation within this domain directly enhance
the binding to mouse CD81.
Alternatively, adaptive changes may act indirectly by eliminat-
ing obstructions that otherwise sterically prevent access of mouse
CD81 to the viral CD81 binding site. In the absence of structural
information of the viral E1/E2 complex we probed the influence
of these mutations on the interaction with CD81 using soluble
human CD81 and CD81-specific antibodies. To phenotypically
distinguish adaptation to mouse CD81 from cell culture
adaptation we compared the mouse CD81-adapted virus to a
recently described cell culture-adaptive mutation within E2
(G451R) that is known to modulate SR-BI and CD81 receptor
usage and virus neutralization [49]. Interestingly, both mutant
viruses interacted more efficiently with soluble human CD81-LEL
and they were both more susceptible to neutralization by this
protein (Figure 3). Previously, Flint et al. were unable to detect
binding of HCV E2 protein to soluble mouse CD81 [25]. Our
attempts to detect changes of HCV binding to soluble mouse
CD81 did not yield conclusive results precluding a definite answer
if the affinity to mouse CD81 was changed by the adaptation (data
not shown). Therefore, it remains to be determined if parental or
adapted HCV binds mouse CD81. Nevertheless, these results
indicate that both virus mutants have a more accessible binding
site for human CD81 which likely facilitates interaction and
neutralization. Such a more open conformation may also assist
interaction with mouse CD81. Notably, also the mouse CD81
adapted virus remains dependent on CD81 since it does not infect
cells devoid of CD81. Therefore, either the adapted HCV indeed
does interact with mouse CD81 or it utilizes an essential function
of mouse CD81 as entry factor even in the absence of direct
binding. As CD81 is a member of the protein family of
tetraspanins, which assemble multi-protein complexes within
membranes, such a function could for instance be the coordination
Figure 8. CD81 dependent infection of NIH3T3 cells expressing human or mouse entry factors by HCVpp. (A) NIH3T3 cell derivatives
transduced with empty expression vectors (NIH3T3 ctrl) or expressing either all four human or mouse HCV entry factors (NIH3T3 4xH, NIH3T3 4xM,
respectively) were challenged with concentrated retroviral pseudoparticles coated with Vesicular stomatitis virus G-protein (VSV-G), wildtype J6CF
glycoproteins (J6/wt) or with mouse CD81 adapted J6CF glycoproteins (J6/mCD81). Lunet N hCD81 cells were inoculated in parallel. Productive
infection was determined by FACS analysis based on Venus-GFP expression derived from the retroviral vector. The HCVpp signal was normalized to
VSV-Gpp infectivity and is expressed relative to HCVpp infectivity determined on our human reference cell line Lunet N hCD81. Mean values including
standard deviations of a representative experiment of five independent experiments are given. (B) Pseudoparticle infection was neutralized with
human and mouse CD81 specific antibodies (5A6 and EAT1 respectively, both Santa Cruz) at the time of inoculation. Note that infections presented in
(A) and (B) were performed in parallel. Control infections performed in the absence of CD81-specific antibodies are displayed in panel (A). Dot Plots of
the experiment are displayed in supplementary figure S7.
doi:10.1371/journal.ppat.1000978.g008
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complex. In line with this notion, a direct interaction between
CD81 and CLDN1 has been reported [50,51].
Interestingly, the mouse CD81 adapted virus was more resistant
to neutralization by CD81-specific antibodies and infected cells
carrying a given abundance of human CD81 at their surface with
increased efficiency compared to wildtype and the Jc1/G451R
variant HCV (Figure 4). These findings suggest that only the
mouse CD81-adaptive changes have enhanced human CD81
receptor usage for infection. Notably, this change however was not
accompanied by a reduction of the minimal threshold CD81
density needed for viral entry (Figure 4B). It is worth mentioning
here that Grove et al. noted decreased neutralization of JFH1
carrying the G451R mutation by CD81-specific antibodies [49].
Although we do not know the reason for this discrepancy it is
possible that the phenotype of this mutation at least with regard to
CD81 usage may differ dependent on the strain of glycoproteins
(J6 and JFH1, respectively).
Receptor competition experiments with antibodies against SR-
BI and CLDN1 revealed a similar behaviour of the mutant viruses,
both exhibiting a decreased SR-BI dependence, while CLDN1-
dependence was indistinguishable between both mutant viruses
and wildtype HCV (Figure 5). Finally, when reducing the number
of available OCLN molecules by RNA interference, both wild type
and the G451R adapted virus were clearly more inhibited than
Jc1/mCD81. These data indicate that both cell culture adaptation
as well as adaptation to mouse CD81 caused reduced SR-BI
dependence, however only the latter procedure at the same time
also reduced dependence on human CD81 and OCLN.
A third possible mechanism that may permit utilization of
mouse CD81 for entry is through facilitating essential conforma-
tional changes of the glycoprotein complex. This could for
instance be mediated by an opening of the overall structure of
the viral surface proteins. Our neutralization experiments with E2-
specific antibodies revealed a much enhanced susceptibility to
neutralization for both mutant viruses. Interestingly, susceptibility
to domain C-specific antibodies was more pronounced for the
mouse CD81 adapted virus than for Jc1 with the G451R
mutation, indicating distinct conformations of the virus particle-
resident E2 proteins at this domain. These findings are both
suggestive of gross conformational changes and of increased
exposure of key neutralizing epitopes. Since these changes were
not accompanied by an altered distribution of these viruses in
density gradients, we believe that they are not due to differential
interaction with lipoproteins. As additional indicator for altered
surface protein conformation and as a measure for viral
responsiveness to triggers of cell membrane fusion, we compared
the ability of wildtype and mutant HCV to infect host cells
stimulated by a low pH wash. In agreement with previous findings,
wildtype HCV was refractory to a low pH wash immediately after
binding to the cell surface at 4uC and only infected cells after an
incubation of 1 h at 37uC [24]. In contrast, both mutant viruses
could be induced to infect cells by low pH directly after binding.
This suggests that the requirements for induction of pH-dependent
fusion have changed for both viruses.
Since the structure of the HCV E1/E2 complex is unknown it is
difficult to finally conclude which of the above mentioned
mechanisms that are certainly not mutually exclusive, is
responsible for the efficient utilization of mouse CD81. Our data
support a model where this combination of mutations leads to an
opening of the glycoprotein complex. This ‘‘unlocked’’ structure
increases exposure of the CD81 binding site and likely in turn
interaction with soluble CD81. Moreover, it also facilitates
conformational changes which may permit the virus to utilize a
weak CD81 binding (e.g. due to interaction with CD81 from non-
human species which bind with low affinity) for its entry process.
In addition, such a conformational change may contribute to
decreased dependence on SR-BI and OCLN and a lower
threshold for pH-triggered cell entry. This interpretation may
also explain why these mutations selected on mouse CD81
increase the usage of rat and hamster CD81 to a comparable
degree (approximately 100-fold). Given that these forms of CD81
differ from each other by a number of amino acids within the viral
binding site [25], this would have been unlikely, if the viral binding
site had specifically adjusted to mouse CD81.
Finally, we show that HCV J6-derived glycoproteins adapted to
mouse CD81 permit infection of mouse cells in the absence of
human factors. Thus, three adaptive mutations within E1 and E2
are sufficient to overcome the barrier for cell entry into mouse
cells. In our view, this finding lends further support to the notion
that these mutations may facilitate receptor-dependent conforma-
tional changes of the glycoproteins thus permitting the use of
mouse CD81 and ultimately infection of cells via solely mouse
factors. Previous reports have established that besides CD81 at
least OCLN poses a strong species barrier to HCV infection
[8,25]. In addition, evidence was reported that sub-optimal usage
of mouse CLDN1 and SR-BI may also limit efficient infection of
mouse cells [26,27]. Therefore, poor entry of HCV into mouse
cells seems to be determined by multiple entry factors, making it
difficult to envision that mere adaptation of the viral CD81
binding site would be sufficient to allow usage of mouse SR-BI,
OCLN, and CLDN1. Notably, while the G451R mutation only
reduced SR-BI-dependence, the mouse CD81 adaptive mutations
at the same time also reduced CD81- and OCLN-dependence
which may be an important prerequisite for the virus to utilize the
foreign entry factors which possibly interact with lower affinity.
Likely due to very low RNA replication of HCV in mouse cells
we were unable to observe productive infection of mouse cells by
Jc1/mCD81 (data not shown). In turn these results highlight that
additional host factors limit propagation of HCV in mouse cells
downstream of virus cell entry. Nevertheless, our findings are
proof of concept that a limited number of mutations can be
sufficient to adapt the virus for usage of foreign host factors or
possibly even host factor complexes and therefore encourage
future efforts to adapt HCV for growth in non-human cells.
Combined with genetic approaches and xenotransplantation [52]
such efforts may ultimately lead to the development of immune
competent small animal models for research of HCV pathogenesis,
immune control as well as vaccine and drug development.
Materials and Methods
Plasmids
The plasmids pFK Jc1, pFK-Luc-Jc1 and pFK-Venus-Jc1 have
been described earlier [37,41,48]. The constructs pFK Jc1/L216F,
pFK Jc1/V388G, pFK Jc1/M405T, pFK Jc1/N767D, pFK Jc1/
V388G/M405T, pFK Jc1/L216F/V388G/M405T (equivalent to
pFK Jc1/mCD81) and pFK Jc1/L216F/V388G/M405T/N767D
were created via PCR-based site-directed mutagenesis. PCR
inserts were sequenced to exclude off site mutations. The
constructs pcDNA3DcE1E2J6/mCD81 (containing L216F,
V388G and M405T) and pcDNA3DcE1E2J6/G451R are deriv-
atives of pcDNA3DcE1E2J6 that has been described recently [26].
pRV Venus was created by insertion of the gene encoding Venus-
GFP [53] into the retroviral vector pczCFG5IZ [54]. Lentiviral
plasmids pWPI humanCD81 BLR, pWPI ratCD81 BLR, pWPI
hamsterCD81 BLR, pWPI mouseCD81 BLR, pWPI hu-
manCD81 Gun, pWPI mouseCD81 Gun, pWPI humanOCLN
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mouseSR-BI Gun, pWPI human CLDN1 BLR and pWPI mouse
CLDN1 BLR encode the human, rat, hamster or mouse orthologs
of the four HCV receptors in the context of the self inactivating
lentiviral vector pWPI [55]. In this context the transgene is
expressed by an internal human elongation factor 1 alpha (EF1-a)
promoter. The transcribed unit also contains an IRES element
from EMCV that allows internal initiation of translation of a
blasticidin S deaminase of Aspergillus terreus or a GFP-ubiquitin
neomycinphosphotransferase fusion protein (Gun) as selectable
markers. Exact cloning strategies and primer sequences can be
obtained on request.
Cell culture
Huh-7.5, Huh7-Lunet, HuH6, 293T and NIH3T3 cells were
cultured in Dulbecco’s modified Eagle medium (DMEM; Invitro-
gen, Karlsruhe, Germany) supplemented with 2 mM L-glutamine,
non-essential amino acids, 100 U of penicillin per ml, 100 mgo f
streptomycin per ml, and 10% fetal calf serum (DMEM complete)
at 37uC and 5% CO2. Lunet N cells were generated by FACS
sorting of CD81 low expressing cells within the Lunet cell
population and subsequent subcloning by limiting dilution. Three
clones were analyzed further with regard to CD81 expression and
permissiveness for HCV RNA replication (clones #3, #4, and
#7). Of these subclones, number #4 and #7 were described
recently [36] and subclone #3 was used throughout this study and
was designated as Lunet N.
Stable cell lines were generated via lentiviral gene transfer as
described recently [56] using the three plasmids pCMVDR.74
[57], a pWPI derivative (either coding for a resistence against
blasticidine (blasticidine S deaminase; BLR) of Aspergillus terreus or a
GFP-ubiquitin-neomycin fusion protein (Gun) and the respective
gene of interest) and pcz VSV-G [58] in a ratio of 3:3:1. Selection
was carried out in the presence of either 5 mg/ml Blasticidin or
0,75 mg/ml G418.
Viruses and HCV pseudoparticles
HCVcc particles and firefly luciferase HCV reporter viruses
were generated as reported previously [48]. In brief, plasmid DNA
was linearized and transcribed into RNA, which was then
electroporated into Huh-7.5 cells. Virus-containing culture
fluids of transfected cells were harvested 48 h and 72 h after
transfection.
Luciferase reporter virus infection assays were carried out and
analyzed as described [48] using Lunet N hCD81 cells as target
cells. Wildtype HCV particles were titrated by using a limiting
dilution assay [59]. The 50% tissue culture infectious dose
(TCID50) was calculated based on the methods described by
Spearman and Ka ¨rber [60,61].
Murine leukemia virus (MLV)-based pseudotypes carrying
vesicular stomatitis virus glycoproteins (VSV-G) or the HCV J6-
derived E1 and E2 proteins as well as their mouse CD81 adapted
derivatives (J6/mCD81) were generated by cotransfection of 293T
cells. Briefly, 1.2610
6 293T cells were seeded into 6-cm-
diameter plates 1 day before transfection with 2.6 mg envelope
protein expression construct pczVSV-G, pcDNA3DcE1E2-J6,
pcDNA3DcE1E2-J6/mCD81 or an empty-vector control, 2.6 mg
MLV Gag-Pol expression construct pHIT60, and 2.6 mg firefly
luciferase transducing vector by using Lipofectamine 2000
(Invitrogen). The medium was replaced 6 h after transfection,
and the supernatants containing the pseudoparticles were
harvested 48 h later. The supernatants were cleared of cells by
passage through a 0.45-mm-pore-size filter, concentrated ca. 10-
fold by ultrafiltration with Amicon Ultra centrifugal filter units
(molecular weight cut off 100 kDa, Millipore, Schwalbach,
Germany) and used to infect Lunet N hCD81 and NIH3T3 cells
and its derivatives expressing HCV entry factors of human and
mouse origin. For infection, target cells were seeded at a cell
density of 2610
4 per well of a 48-well plate 24 h prior to
inoculation. Cells were inoculated for 4 h with retroviral
pseudoparticles and cells were cultured an additional 48 h prior
to harvesting and fixation in 1% paraformaldehyde (PFA) w/v.
Venus GFP-expression as marker for productively infected cells
was quantified using a FACS-Calibur flow cytometer (Becton
Dickinson, Heidelberg, Germany) and the Flow Jo software
package. Raw FACS scatter plots of one representative experiment
of five independent repetitions are depicted in supplementary
Figure S7. A representative experiment carried out in duplicates
from 5 independent experiments is depicted in Figure 7. The
background Venus-GFP signal from non-enveloped pseudoparti-
cles (Env-pp) was first subtracted from the VSV-Gpp and HCVpp
signals. The HCVpp signal was then normalized to VSV-Gpp
infectivity [(HCVpp-NE)/(VSVG-NE)]. Finally, these values were
expressed relative to HCVpp infectivity determined on our human
reference cell line Lunet N hCD81. As a result, the data reflect the
relative ability of HCVpp to infect mouse NIH3T3 cells expressing
different human or mouse entry factors compared to highly
permissive human host cells (Lunet N hCD81).
CD81 interaction assays
CD81 LEL GST fusion proteins were prepared as described
[25]. In brief the expression constructs were transformed in E.coli
rosetta gami. A 1 l culture of the bacteria was grown to an OD592 of
0.8 at 37uC and induced to express the GST fusion proteins with
1 mM IPTG (Sigma-Aldrich, Steinheim, Germany) at RT over
night. Bacteria were first lysed with 1 mg/ml chicken egg
lysozyme (Sigma) and 500 U benzonase in PBS and in a second
step with 0.5% nonidet P-40 (NP40) in PBS (lysis buffer) the
supernatant was incubated with 2 ml of a 1:1 slurry glutathione
agarose (Sigma) for 2 h at RTunder gentle agitation washed three
times with 25 ml lysis buffer and afterwards the bound proteins
were eluted with 100 mM Glutathione (Sigma-Aldrich, Steinheim,
Germany) in PBS and dialysed in PBS over night. Concentrations
were determined by Bradford.
To determine the interaction between the recombinant CD81
protein and virus particles, 500 ml virus-containing culture fluid
harvested 48 h post transfection of Huh-7.5 cells and normalized
for the amount of Core protein were preincubated with 50 ml
glutathione agarose beads (1:1 slurry). These preadsorbed virus
preparations were incubated with 50 ml glutathione agarose beads
that had been coupled with 10 mg recombinant GST-CD81-LEL
proteins and the mixture was incubated on a rotator at 4uC over
night. Subsequently, beads were washed 3 times with PBS and
then resuspended in 200 ml of PBS. The amount of bead-
associated HCV core protein was determined by a commercial
core-specific ELISA (Wako Chemicals, Neuss, Germany). HCV
RNA associated with beads suspended in 100 ml PBS was
extracted using the Nucleo Spin RNAII kit (Macherey-Nagel,
Du ¨ren, Germany) as recommended by the manufacturer. Two
microliters of the RNA sample were used for quantitative RT-
PCR analysis using a LightCycler 480 (Roche, Mannheim,
Germany). HCV-specific RT-PCRs were conducted in duplicate
employing a one-step RT-PCR LightCycler 480 RNA Master
Hydrolysis Probes kit (Roche, Mannheim, Germany) and the
following JFH1-specific probe (TIB Molbiol, Berlin, Germany)
and primers (MWG-Biotech, Martinsried, Germany): A-195 [59-
6FAM (6-carboxyfluorescein)-AAA GGA CCC AGT CTT CCC
GGC AAT T-TAMRA (tetrachloro-6-carboxyfluorescein)-39], S-
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GGG CAT AGA GTG GGT TTA TCC A-39).
Neutralization assays
Luc-Jc1viruses were incubated with different concentrations of the
indicated antibodies for 30 minutes at RT prior to inoculation of
Lunet N hCD81 cells which had been seeded at a density of 0.7610
4
cell/96-well the day before. Each neutralization assay was conducted
in triplicates with a total volume of 100 ml/well. 4 h after inoculation
with the virus/antibody mixture another 100 mlo fm e d i u mw a s
added. Anti-E2 neutralization assays were conducted using the
human E2-specific mAbs CBH4D, CBH23, CBH5, and the R04
antibody which is directed against a cytomegalovirus protein as
control [46,62], and the E2-specific mouse monoclonal antibody
AP33 [63]. For receptor neutralization assays the mouse monoclonal
anti CD81 antibody 5A6 (Santa Cruz, Santa Cruz, CA) and 1.3.3.22
(Ancell, Bayport, MN) or anti-CD13 (Beckton Dickenson, Heidel-
berg, Germany) were utilized. IgGs from polyclonal rat sera specific
to SR-B1 and CLDN1, raised by genetic immunization of Wistar rats
with a plasmid expressing the respective full length cDNA, were
produced and purified as described [64], and employed at the
indicated concentrations starting with 50 mg/ml.
RNA interference
SiRNA pools from Dharmacon (Lafayette, CO) specific to
human OCLN were transfected via reverse transfection according
to the manufacturer’s instructions using RNAiMax (Invitrogen)
into Lunet N hCD81 cells. Briefly, 150 pmol siRNA were mixed
with 200 ml OptiMEM in a 12-well, and 1.5 ml of RNAiMax were
added. A total of 6610
4 Lunet N hCD81 cells suspended in 1 ml
of plain medium with 10% FCS were seeded on top. Knock down
efficiency was analyzed 48 h after transfection via Western Blot
directly at the time of inoculation with HCV luciferase reporter
viruses. Infection efficiency was determined 48 h later using
luciferase assays as described above.
Initiation of HCV infection by low pH wash
The assay was conducted as described earlier [24,65]. Lunet N
hCD81 cells were seeded at a density of 2.5610
5 cells/6-well. 24 h
later, cells were pretreated with Concanamycin A (ConA; 5 nM) for
1 h at 37uC. Subsequently, cells were shifted to 4uC and were then
infected with F-Luc Jc1 variants in the presence of ConA for 2 h at
4uC. Cells were washed twice with cold PBS either directly followed
by an incubation in citric acid buffer (McIllivaine’s buffer system
pH 7 or 5) for 5 min at 37uC. Alternatively, after virus binding at
4uC, cells were first shifted to 37uC for 1 h under continued
presence of ConA to 37uC, and only then incubated with citric acid
buffer as described above. In both protocols, cells were maintained
for another 3 h in medium containing 5 nM ConA and then the
medium was replaced. Cells were lysed after 48 h and the luciferase
signal was measured. Luciferase values are expressed relative to
control infections which were conducted in the absence of ConA
and with an incubation step with citric acid buffer of pH 7.
Densitiy gradient
HCV particles were harvested 48 h after electroportation of
Huh-7.5 with the indicated viral RNA. 1 ml of virus containing
supernatant was mixed with 2 ml of a 60% (w/v) iodixanol stock
solution (Optiprep Axis Shield, Oslo, Norway) and layered under a
0–30% iodixanol gradient. Gradients were centrifuged at
154,0006g for 18 h and afterwards 1 ml fractions were collected
from bottom to top. The density of the different fractions was
determined via refractometry, the infectivity was determined in
limiting dilution assay and the amount of particles was assessed by
the determination of RNA copies as described above.
Flow cytometry
5610
5 cells were stained with antibodies specific for hCD81
(5A6, 1:200, Ancell, Bayport, MN) for mCD81 (EAT2-PE, 1:20,
Santa Cruz, Santa Cruz, CA) or with a polyclonal rabbit serum
directed against SR-BI (Novus Biologicals, Littleton, CO 1:50) in
PBS containing 2% FCS for 30 minutes on ice and washed with
PBS. In case of noncoupled primary antibodies bound antibodies
were detected with secondary antibodies coupled to phycoerythrin
or allophycocyanin (1:200, eBioscience, San Diego, CA) for 30
minutes on ice. After a next washing step the cells were analyzed
with a FACS Calibur (Becton Dickinson, Heidelberg, Germany)
and the results were analyzed using the Flow Jo Software.
Western blot analysis
Cells were washed with PBS and lysed in RIPA buffer (0.3 M
NaCl, 20 mM TrisHCl pH 8, 1% Sodium dexoxycholat; 0.1%
SDS and 1% Triton) for 30 minutes on ice. The total protein
content was determined by Bradford assay. Equal protein amounts
for each sample were mixed with 26 denaturing protein sample
buffer (200 mM Tris-HCl [pH 8.8], 5 mM EDTA, 0.1%
bromophenol blue, 10% sucrose, 3.3% sodium dodecyl sulfate
[SDS], 2% 2-mercaptoethanol [2-ME]) for 5 minutes at 98uC,
loaded onto a 12.5% SDS-gel and resolved by electrophoresis.
Subsequently, proteins were transferred with a semiydry blotter to
a polyvinylidene difluoride membrane. The membrane was
blocked with 5% milk in PBS containing 0.5% Tween (PBS-T)
for 1 h at RT. CLDN1, OCLN and actin were detected with
specific monoclonal antibodies (Zymed, San Francisco, CA and
Sigma-Aldrich, Steinheim, Germany) and a secondary antibody
coupled to the horseradish peroxidase (Sigma-Aldrich, Steinheim,
Germany). The antibody signal was detected with the ECL Plus
detection system (GE Healthcare, Freiburg, Germany).
Statistical analysis
Comparison of knock down of OCLN reduced entry of Jc1,
Jc1/G451R, and Jc1/mCD81 were compared with one-way
analysis of variance of hill functions. Similarly, the proportion of
infected cells according to their MFI is fitted by nonlinear
weighted least squares. IC90 values from neutralization experi-
ments were obtained and compared by nonlinear least squares fit
of hill functions. All tests were two-sided and p-values below 5%
are considered significant.
Supporting Information
Figure S1 Characterization of Lunet N cells. (A) FACS analysis
for the expression of human and mouse CD81 and SR-BI of Lunet
N, Lunet N mCD81 and Lunet N hCD81 cells. Human CD81 was
detected with the mouse monoclonal antibody 5A6 (Santa Cruz)
and a secondary antibody coupled to APC. Mouse CD81 was
detected with the monoclonal hamster antibody EAT2 directly
coupled to PE (Santa Cruz) and SR-BI was detected with a
polyclonal rabbit serum (Novus Biologicals) and secondary
antibodies coupled to Alexa488 (Invitrogen). (B) Western Blot
analysis of the tight junction proteins CLDN1 and OCLN (both
antibodies from Zymed). Actin expression was determined to
ensure equal sample loading. (C) HCV RNA replication in
transfected Lunet N cells. The different Lunet N cells were
transfected with F-Luc Jc1 RNA and lysed at the indicated time
points to measure the reporter activity. To normalize for different
transfection efficiency values are expressed relative to the luciferase
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duplicate measurements are given. (D) Infectivity of HCV in
different Lunet N cells. Virus supernatants harvested from Huh-
7.5 cells 48 h after transfection were titrated using the limiting
dilution assay (TCID50) on the indicated Lunet N cell lines. The
dashed line indicates the detection limit of the limiting dilution
assay. Epo, electroporation.
Found at: doi:10.1371/journal.ppat.1000978.s001 (1.36 MB EPS)
Figure S2 Adaptation of HCV to mouse CD81 through serial
passage in Lunet N mCD81 cells. Cell free culture fluids were
collected at indicated steps of the cell culture adaptation procedure
and frozen. At the end of the experiments, all samples were titrated
in parallel using Lunet N, Lunet N mCD81 and Lunet N hCD81
as target cells. The dashed line indicates the detection limit of the
limiting dilution assay.
Found at: doi:10.1371/journal.ppat.1000978.s002 (0.32 MB EPS)
Figure S3 CD81 usage by Jc1/G451R. Huh-7.5 cells were
transfected with Jc1/wt, Jc1/mCD81 or Jc1/G451R RNA and
the cell culture supernatant was titrated by the limiting dilution
assay on Lunet N hCD81 or Lunet mCD81 cells. The dashed line
indicates the detection limit of the limiting dilution assay.
Found at: doi:10.1371/journal.ppat.1000978.s003 (0.29 MB EPS)
Figure S4 Infection of Lunet cells with diverse CD81 expression
with Venus-GFP reporter viruses. Naı ¨ve Huh7-Lunet cells were
mixed with Lunet N hCD81 cells in a ratio of 1:1 and were seeded
one day prior to infection with Venus Jc1 reporter viruses
normalized for equal amounts of core protein. 72 h after infection
the cells were harvested, fixed and stained for CD81 with the CD81
specific antibody 5A6 and a secondary antibody coupled to APC.
The Venus GFP signal was plotted against the CD81 expression.
Mixed Lunet cells were infected with Venus Jc1 reporter viruses
bearing the adaptive mutations and normalized for the amount of
Core protein. Depicted are representative dot plots of uninfected
cells or cells infected with the indicated Venus Jc1 reporter viruses.
Found at: doi:10.1371/journal.ppat.1000978.s004 (1.18 MB EPS)
Figure S5 Biophysical properties of HCV particles. Cell culture
supernatants containing virus particles harvested 48 h after
transfection of given HCV genomes were layered under a linear
iodixanol gradient. 10 fractions were collected after ultracentrifu-
gation and analyzed for the infectivity on Lunet N hCD81 cells.
The density of each fraction was determined by refractometry.
The infectivty (A) and the HCV RNA copy numbers (B) in each
fraction were determined by the limiting dilution assay and
quantitative RT-PCR, respectively. The specific infectivity (C) was
calculated for each fraction and is expressed relative to a single
HCV RNA genome.
Found at: doi:10.1371/journal.ppat.1000978.s005 (0.42 MB EPS)
Figure S6 Receptor expression on NIH3T3 cells stably
expressing HCV entry factors from mouse or human origin. (A)
FACS analysis for the expression of human and mouse CD81 and
SR-BI on the surface of NIH3T3 control cells transduced with the
empty expression vector (NIH3T3 ctrl), NIH3T3 cells transduced
with the four human entry factors(NIH3T3 4xH) or the four
mouse entry factors (NIH3T3 4xM). Human CD81 was detected
with the mouse monoclonal antibody 5A6 (Santa Cruz) and a
secondary antibody coupled to APC. Mouse CD81 was detected
with the monoclonal hamster antibody EAT2 coupled to PE
(Santa Cruz). SR-BI expression was determined with a polyclonal
rabbit serum (Novus Biologicals) reactive with both human and
mouse SR-BI and a secondary antibody coupled to FITC. Grey
histograms represent unstained cells. (B) Western Blot analysis of
human or mouse CLDN1 and OCLN expressed in NIH3T3 cell
derivatives. Both CLDN1- and OCLN-specific antibodies were
from Zymed.
Found at: doi:10.1371/journal.ppat.1000978.s006 (1.30 MB EPS)
Figure S7 CD81 dependent infection of NIH3T3 cells stably
expressing HCV entry factors of mouse or human origin with
HCVpp. (A) NIH3T3 derived cell lines and Lunet N hCD81 cells
were infected with concentrated MLV based pseudoparticles
transducing Venus-GFP as reporter gene and carrying no
envelope protein, the J6/wt glycoproteins, the J6/mCD81
glycoproteins, or as a control VSV-G. Cells were harvested 48 h
after inoculation and the amount of infected cells was determined
by flow cytometry and is depicted in the Dot Plots. (B)
Neutralization of HCVpps with CD81 specific antibodies. Lunet
N hCD81 cells were neutralized with the human CD81 specific
antibody 5A6 and NIH3T3 4xM cells with the mouse CD81
specific antibody EAT1 (both Santa Cruz). Note that infections
presented in (A) and (B) were performed in parallel. Control
infections performed in the absence of CD81-specific antibodies
are displayed in panel (A).
Found at: doi:10.1371/journal.ppat.1000978.s007 (3.05 MB EPS)
Figure S8 Characterization of HCV receptor expression in
primary mouse hepatocytes. (A) Hepatocytes from C57BL/6 mice
were isolated by a two-step collagenase perfusion method as
described [66]. The expression of mouse CD81 and mouse SR-BI
on the surface of primary mouse hepatocytes was determined by
FACS analysis. CD81 was detected with the monoclonal hamster
antibody EAT2 coupled to PE (Santa Cruz). SR-BI expression was
determined with a polyclonal rabbit serum (Novus Biologicals) and
a secondary antibody coupled to PE. Grey histograms represent
unstained cells. (B) Western blot analysis of CLDN1 and OCLN
expression in primary mouse hepatocytes. NIH3TE 4xM cells
served as positive control. Both CLDN1- and OCLN-specific
antibodies were from Zymed.
Found at: doi:10.1371/journal.ppat.1000978.s008 (1.76 MB EPS)
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